Skip to main content

Table 1 Clinicopathological characteristics of OSC patients from TCGA

From: A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

Characteristics Groups Patients
   Total (N = 551) Training dataset (N = 368) Validation dataset (N = 183)
No. % No. % No. %
Age at diagnosis Median 59   60   59  
Range 26–89   34–87   30–89  
< 60 286 50.44 187 50.95 104 63.41
≥ 60 265 46.74 182 49.59 79 48.17
FIGO stage I 15 2.65 5 1.36 10 6.10
II 27 4.76 12 3.27 15 9.15
III 423 74.60 287 78.20 136 82.93
IV 82 14.46 62 16.89 20 12.20
Unknown 4 0.71 2 0.54 2 1.22
Histologic grade* G2 69 12.17 25 6.81 44 26.83
G3 478 84.30 341 92.92 137 83.54
G4 1 0.18 1 0.27 0 0.00
Others 3 0.53 1 0.27 2 1.22
Tumor residual (mm) No macroscopic disease 116 20.46 67 18.26 49 29.88
1–10 244 43.03 191 52.04 53 32.32
11–20 33 5.82 16 4.36 17 10.37
> 20 105 18.52 64 17.44 41 25.00
Unknown 53 9.35 33 8.99 25 15.24
Anatomic subdivision Bilateral 383 67.55 253 68.94 130 79.27
Left 78 13.76 55 14.99 23 14.02
Right 62 10.93 40 10.90 22 13.41
Unknown 28 4.94 20 5.45 8 4.88
  1. *G1 and GB/GX were excluded in this study as these tumors may have a different biological behavior